Novartis Venture Fund
Novartis Venture Fund is a venture capital firm focused on companies that develop novel therapeutics and platforms.
Business Model:
Revenue: $34.4M
Employees: 51-200
Rankings
Industries / Tags:
Detailed Novartis Venture Fund Information
Geographic Data
Address: 355 Main St
City: Cambridge
State: MA
Zip: 02142
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Twitter
Linkedin
Crunchbase
Metrics
9,316,027Website Global Rank
166Website Monthly Traffic
Twitter Followers
Description
Our primary focus is on the development of novel therapeutics and platforms. We balance the therapeutic focus with investments in medical devices, diagnostics or drug delivery systems. In our investments we look for unmet need and clinical impact, novel proprietary science and understanding of mechanism, management and board experience and capital efficiency in the program. We prefer to have our initial investment at the early stage to build the company and follow with additional investment in pace with the company:tm:s progress. We continue our approach of larger focused investments and anticipate total investments up to USD 30 to 50 mio per company over its life, but it can be as little as 100&s;000 USD to get started. We will increase our activities to lead or co-lead deals further and remain open to participate in larger syndicates. Sectors New therapeutics &a; platforms Medical devices/implants Diagnostics/biomarkers Drug delivery/biopolymers Geography USA/Canada Europe Switzerland Asia/Pacific
Contact Phone:
+16178713536
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 1/2019 | Occlufit | Venture Round | - |
| 2/2015 | Altimmune | Post-IPO Equity | 16M |
| 7/2010 | Euthymics Bioscience | Series A | 24M |
| 10/2015 | Galera Therapeutics | Series B | 37M |
| 10/2012 | Thesan Pharmaceuticals | Series A | 16M |
| 7/2001 | Nereus Pharmaceuticals | Series B | 23.6M |
| 7/2007 | Neovacs | Venture Round | 17.9M |
| 7/2007 | Immune Targeting Systems | Series A | 7.1M |
| 6/2010 | Foldrx Pharmaceuticals | Venture Round | 29M |
| 11/2013 | Aileron Therapeutics | Series E | 30M |
| 5/2007 | ProCertus BioPharm | Series A | 2.3M |
| 7/2009 | ProCertus BioPharm | Venture Round | 2.1M |
| 8/2019 | Renovacor | Series A | 11M |
| 2/2009 | Alios BioPharma | Series A | 8.4M |
| 6/2009 | Eledon Pharmaceuticals | Series D | 22M |
| 10/2006 | Biofisica | Series A | 5M |
| 1/2006 | EraGen Biosciences | Series A | 12M |
| 1/2020 | TScan Therapeutics | Series B | 35M |
| 9/2004 | Nura | Series A | 9.5M |
| 11/2014 | Bionano Genomics | Series C | 0 |
| 12/2009 | Evolva | Post-IPO Equity | 27.5M |
| 4/2011 | Akebia Therapeutics | Series B | 0 |
| 9/2010 | Cylene Pharmaceuticals | Series D | 12M |
| 5/2020 | mPharma | Series C | 0 |
| 2/2019 | Anaveon | Series A | 35M |
| 11/2021 | Kedalion Therapeutics | Series B | - |
| 7/2009 | Viamet Pharmaceuticals | Series B | 25M |
| 5/2014 | Sorbent Therapeutics | Series D | 0 |
| 6/2011 | Sorbent Therapeutics | Series B | 0 |
| 9/2018 | Twentyeight-Seven Therapeutics | Series A | 65M |
| 10/2009 | Evolva | Series B | 27.8M |
| 8/2021 | Immunitas Therapeutics | Series B | 0 |
| 10/2014 | Viamet Pharma | Series D | 60M |
| 6/2015 | Myopowers Medical Technologies | Series C | 5.1M |
| 5/2003 | GlycoMimetics | Series A | 4.3M |
| 8/2018 | Artios Pharma | Series B | 0 |
| 7/2009 | Akebia Therapeutics | Series A | 25M |
| 8/2016 | Bionano Genomics | Series D | 31.7M |
| 7/2011 | Myopowers Medical Technologies | Series B | 16M |
| 2/2012 | Celladon | Venture Round | 43M |
| 2/2009 | Heptares Therapeutics | Series A | 30M |
| 3/2005 | TorreyPines Therapeutics | Series C | 0 |
| 10/2005 | Nereus Pharmaceuticals | Series D | 0 |
| 3/2023 | Mediar Therapeutics | Series A | 0 |
| 6/2007 | BioRelix | Series A | 25.8M |
| 6/2015 | Realeve | Series D | 43.2M |
| 3/2023 | Oculis | Post-IPO Equity | 0 |
| 12/2020 | Faze Medicines | Series A | 81M |
| 5/2001 | AGY | Series B | 13M |
| 6/2023 | Tagworks Pharmaceuticals | Series A | 65M |
| 11/2003 | Roche Glycart | Series A | 13.6M |
| 6/2023 | Tagworks Pharmaceuticals | Series A | 0 |
| 2/2022 | Splice Bio | Series A | 0 |
| 1/2018 | Oculis | Series B | 20.5M |
| 8/2006 | Kemia | Series C | 0 |
| 9/2021 | Flywheel.io | Series C | 0 |
| 2/2014 | Aeglea BioTherapeutics | Series A | 0 |
| 7/2021 | Artios Pharma | Series C | 0 |
| 5/2002 | Kalypsys | Series A | 42M |
| 7/2015 | GenSight Biologics | Series B | 0 |
| 5/2021 | Oculis | Series C | 0 |
| 5/2002 | ESBATech | Series A | 0 |
| 6/2015 | Kanyos Bio | Venture Round | 16.4M |
| 7/2019 | Forendo Pharma | Venture Round | 0 |
| 2/2006 | EyeSense AG | Series A | 0 |
| 10/2002 | MerLion Pharma | Series A | 0 |
| 1/2010 | Merus | Series B | 0 |
| 3/2007 | Okairos | Series A | 9.6M |
| 11/2006 | Intradigm Corporation | Series A | 16M |
| 6/2005 | Amphora Discovery | Series D | 9.6M |
| 2/2007 | Trellis Bioscience | Series B | 10M |
| 5/2001 | Polyphor | Venture Round | 9.3M |
| 2/2015 | Merganser Biotech | Series A | 28M |
| 5/2017 | Lemonaid Health | Series A | 0 |
| 2/2008 | Biofisica | Venture Round | 2.4M |
| 10/2011 | Realeve | Series C | 32M |
| 11/2021 | LOQUS23 THERAPEUTICS | Seed Round | 0 |
| 3/2017 | Aerpio Pharmaceuticals | Venture Round | 0 |
| 3/2015 | Zikani Therapeutics | Series A | 22M |
| 6/2007 | Tepha | Series B | 0 |
| 1/2022 | ImmPACT Bio | Series B | 0 |
| 3/2015 | Aeglea BioTherapeutics | Series B | 44M |
| 4/2014 | Aerpio Pharmaceuticals | Series C | 0 |
| 10/2012 | Neurovance | Venture Round | 7M |
| 1/2017 | Cavion | Series A | 0 |
| 4/2014 | Neurovance | Series A | 6.3M |
| 8/2021 | GentiBio | Series A | 157M |
| 11/2007 | Ascent Therapeutics | Series A | 19M |
| 3/2012 | BioRelix | Venture Round | 2.6M |
| 5/2013 | Effector Therapeutics | Series A | 45M |
| 4/2006 | Sirtris Pharmaceuticals | Series C | 37M |
| 9/2020 | Novellus | Series C | 57M |
| 1/2000 | Viron Therapeutics | Series A | - |
| 9/2009 | PharmAbcine | Series A | 6M |
| 6/2010 | NanoPowers | Series A | 0 |
| 2/2014 | Thesan Pharmaceuticals | Series B | 49M |
| 4/2014 | Alios BioPharma | Series B | 41M |
| 9/2018 | Galera Therapeutics | Series C | 70M |
| 8/2004 | GlycoMimetics | Series A | 5.1M |
| 2/2016 | Galera Therapeutics | Series B | 0 |
| 7/2017 | NeuroVia | Series A | 14M |
| 10/2009 | Nabriva Therapeutics | Venture Round | 0 |
| 8/2014 | Galera Therapeutics | Series A | 4.7M |
| 6/2006 | GlycoMimetics | Series B | 0 |
| 3/2007 | Phenomix | Series C | 55M |
| 7/2009 | Avila Therapeutics | Series B | 30M |
| 4/2015 | Nabriva Therapeutics | Series B | 0 |
| 11/2005 | PTC Therapeutics | Private Equity Round | 26.6M |
| 6/2007 | Aileron Therapeutics | Series B | 7M |
| 6/2009 | Alios BioPharma | Series A | 24M |
| 4/2007 | Protemix | Series A | 14.5M |
| 4/2012 | Advanced Animal Diagnostics | Series B | 4M |
| 6/2009 | Opsona | Series B | 4.6M |
| 5/2009 | NovImmune | Venture Round | 0 |
| 9/2016 | Inflazome | Series A | 17M |
| 10/2013 | Opsona | Series C | 0 |
| 4/2013 | Opsona | Series C | 0 |
| 12/2012 | Bicycle Therapeutics | Venture Round | 6M |
| 3/2022 | Epsilogen | Series B | 0 |
| 9/2020 | ESCAPE Bio | Venture Round | 73M |
| 10/2020 | Rappta Therapeutics | Series A | 10.6M |
| 10/2014 | Forendo Pharma | Series A | 0 |
| 7/2017 | ESCAPE Bio | Series A | 63M |
| 8/2004 | Evolva | Series A | 14.8M |
| 4/2008 | Aileron Therapeutics | Series C | 10.5M |
| 2/2006 | Catalyst Biosciences | Series B | 30M |
| 6/2009 | Aileron Therapeutics | Series D | 40M |
| 12/2021 | IKAS Industrial Automation | Series B | 0 |
| 1/2018 | Expansion Therapeutics | Series A | 55.3M |
| 4/2018 | Enterprise Therapeutics | Series B | 41.3M |
| 8/2020 | ImmPACT Bio | Series A | 0 |
| 8/2012 | Sorbent Therapeutics | Series C | 18.1M |
| 6/2016 | Annexon Biosciences | Series B | 44M |
| 9/2022 | Capstan Therapeutics | Series A | 102M |
| 12/2018 | Annexon Biosciences | Series C | 75M |
| 3/2021 | Amphista Therapeutics | Series B | 0 |
| 11/2022 | DJEL | Venture Round | 139.4M |
| 4/2013 | Catalyst Biosciences | Post-IPO Equity | 5.1M |
| 1/2015 | Binx Health | Series C | 0 |
| 9/2011 | Eledon Pharmaceuticals | Series D | 23M |
| 6/2002 | Infinity Pharmaceuticals | Series B | 0 |
| 3/2011 | Euthymics Bioscience | Series A | 4M |
| 10/2009 | Covagen | Seed Round | - |
| 11/2010 | Covagen | Series A | 6.3M |
| 1/2017 | Binx Health | Series D | 0 |
| 10/2004 | Miikana Therapeutics | Series A | 3M |
| 3/2008 | LigoCyte Pharmaceuticals | Series C | 29.5M |
| 1/2009 | Intradigm Corporation | Series B | 0 |
| 12/2006 | Evolva | Series A | 10.3M |
| 12/2008 | Diagnoplex | Series A | 8.3M |
| 10/2014 | Aileron Therapeutics | Series E | 33M |
| 1/2021 | TScan Therapeutics | Series C | 100M |
| 12/2009 | FORMA Therapeutics | Series B | 3M |
| 4/2011 | ProCertus BioPharm | Series A | 1.7M |
| 8/2010 | Anchor Therapeutics | Series B | 10M |
| 4/2008 | FORMA Therapeutics | Series A | 4M |
| 1/2016 | Adicet Bio | Series A | 51M |
| 2/2007 | Omeros | Series E | 0 |
| 3/2015 | Galera Therapeutics | Series A | 4.7M |
| 12/2005 | Santhera Pharmaceuticals | Series B | 0 |
| 5/2021 | Soteria Biotherapeutics | Series A | 42M |
| 11/2021 | Capstan Therapeutics | Seed Round | 63M |
| 3/2010 | Immune Targeting Systems | Series A | 13.2M |
| 6/2006 | NovImmune | Series B | 0 |
| 7/2011 | Binx Health | Series B | 27.1M |
| 3/2012 | ImaginAb | Series A | 12.5M |
| 10/2001 | Cylene Pharmaceuticals | Series A | 3.5M |
| 10/2009 | Bicycle Therapeutics | Seed Round | - |
| 10/2014 | Quartet Medicine | Series A | 17M |
| 10/2013 | Merus | Series B | 42.2M |
| 11/2022 | CatalYm | Series C | 0 |
| 12/2013 | Covagen | Series B | 0 |
| 12/2021 | Anaveon | Series B | 0 |
| 9/2019 | Adicet Bio | Series B | 0 |
| 3/2005 | Evolva | Series A | 2.6M |
| 7/2009 | Intellikine | Series B | 51M |
| 8/2008 | ESBATech | Series B | 22M |
| 12/2008 | Catalyst Biosciences | Post-IPO Equity | 40M |
| 6/2007 | Cequent Pharmaceuticals | Series A | 9M |
| 8/2004 | AGY Therapeutics | Series C | 9M |
| 5/2014 | Anokion | Series A | 37.5M |
| 6/2017 | Bicycle Therapeutics | Series B | 52M |
| 11/2020 | Catalym | Series B | 59.3M |
| 8/2006 | ESBATech | Series B | 41M |
| 10/2014 | Bicycle Therapeutics | Series A | 32M |
| 12/2017 | Aelin Therapeutics | Series A | 31.8M |
| 4/2015 | Merus | Series C | 79.1M |
| 8/2011 | Pulmatrix | Series B | 14M |
| 5/2019 | Twentyeight-Seven Therapeutics | Series A | 15M |
| 11/2009 | Pulmatrix | Series B | 30.2M |
| 4/2020 | FoRx Therapeutics | Seed Round | 10.8M |
| 1/2010 | MicroCHIPS | Venture Round | 16.5M |
| 8/2014 | YourBio Health | Series B | 16M |
| 12/2015 | Effector Therapeutics | Series B | 40M |
| 1/2019 | Ribon Therapeutics | Series B | 65M |
| 12/2009 | GlycoMimetics | Series C | 0 |
| 5/2019 | Cala Health | Series C | 0 |
| 12/2012 | Galera Therapeutics | Series A | 11M |
| 11/2013 | Aerpio Pharmaceuticals | Series A | 0 |
| 12/2004 | Amphora Discovery | Series C | 20M |
| 11/2009 | Oxagen | Series C | 0 |
| 7/2017 | Effector Therapeutics | Series C | 38.6M |
| 3/2020 | Akouos | Series B | 105M |
| 8/2018 | Akouos | Series A | 25.1M |
| 7/2019 | TScan Therapeutics | Series B | - |
| 9/2018 | Forendo Pharma | Venture Round | 0 |
| 4/2013 | GenSight Biologics | Series A | 41.7M |
| 7/2009 | Symetis | Series B | 0 |
| 5/2015 | Realeve | Series D | 38M |
| 8/2008 | Proteostasis Therapeutics | Series A | 45M |
| 5/2006 | Foldrx Pharmaceuticals | Series B | 43M |
| 4/2014 | Binx Health | Series B | 0 |
| 1/2010 | Cellerix | Series C | 37.7M |
| 11/2009 | Cellerix | Series B | 40.5M |
| 9/2007 | Cellerix | Series B | 37.2M |
| 5/2017 | Vivet Therapeutics | Series A | 41.2M |
| 10/2021 | Exo Therapeutics | Series B | 0 |
| 9/2020 | Fore Biotherapeutics | Series C | 57M |
| 6/2021 | Ribon Therapeutics | Series C | 0 |
| 4/2007 | MicroCHIPS | Venture Round | 13.4M |
| 12/2014 | Annexon Biosciences | Series A | 34M |
| 3/2011 | Advanced Animal Diagnostics | Series B | 11M |
| 12/2019 | Arctos Medical | Seed Round | 0 |
| 9/2012 | F2G | Equity | 30M |
| 9/2015 | Proteostasis Therapeutics | Series B | 37M |
| 12/2020 | Exo Therapeutics | Series A | 25M |
| 4/2018 | Zikani Therapeutics | Venture Round | 0 |
| 5/2009 | Visiogen | Series D | 40M |
| 9/2012 | FORMA Therapeutics | Series C | 10M |
| 3/2016 | Bionano Genomics | Series D | 9.9M |
| 2/2005 | Covalys Biosciences | Series B | 2.6M |
| 9/2019 | Anokion | Series B | 40M |
| 1/2001 | Acorda Therapeutics | Series A | 0 |
| 7/2007 | Ablation Frontiers | Series C | 0 |
| 11/2004 | Symetis | Series A | 9.6M |
| 6/2013 | Akebia Therapeutics | Series C | 0 |
| 6/2016 | F2G | Series E | 60M |
| 12/2009 | FORMA Therapeutics | Series B | 25.5M |
| 7/2015 | Ra Pharmaceuticals | Series B | 58.5M |
| 5/2013 | Eledon Pharmaceuticals | Series E | 35.5M |
| 9/2016 | Rox Medical | Series E | 40M |
| 5/2000 | NovImmune | Series A | 14M |
| 9/2021 | Expansion Therapeutics | Series B | 80M |
| 8/2020 | GentiBio | Seed Round | 20M |
| 1/2013 | Aileron Therapeutics | Series D | 12M |
| 12/2006 | Aileron Therapeutics | Series A | 7M |
| 5/2014 | ImaginAb | Series B | 21M |
| 4/2013 | Advanced Animal Diagnostics | Series B | 6M |
| 3/2022 | Epsilogen | Series B | 0 |
| 2/2022 | Splice Bio | Series A | 0 |
| 1/2022 | ImmPACT Bio | Series B | 0 |
| 12/2021 | IKAS Industrial Automation | Series B | 0 |
| 12/2021 | Anaveon | Series B | 0 |
| 11/2021 | LOQUS23 THERAPEUTICS | Seed Round | 0 |
| 11/2021 | Kedalion Therapeutics | Series B | - |
| 10/2021 | Exo Therapeutics | Series B | 0 |
| 9/2021 | Expansion Therapeutics | Series B | 0 |
| 9/2021 | Flywheel.io | Series C | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
